Bridge Biotherapeutics Signs a License Agreement with Konkuk University for its Back-Eye Disease Therapy

Shots:

• Konkuk University to receive $0.25M upfront, ~$8.1M development and commercial milestones while Bridge Biotherapeutics to get WW exclusive license for the compound and will lead preclinical and development process of the therapy
• Additionally, in 2019, Bridge Biotherapeutics signed a license agreement with Boehringer Ingelheim to develop BBT-877, an autotaxin inhibitor targeting fibrosing interstitial lung diseases including IPF
• Bridge Biotherapeutics’ pipeline includes BBT-401, being evaluated in P-II study for UC and BBT-176, a potent targeted cancer therapy for NSCLC

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Bridge Biotherapeutics